**IVABRADINE**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Manner of administration and form  Oral, 5mg tablet: film-coated | | Max.  Qty | №.of  Rpts | Dispensed Price for Max. Qty | Proprietary Name and Manufacturer | |
| DRUG NAME (IN CAPITALS)  **IVABRADINE**  {Forms(s)} {strength(s)}  5mg tablet: film-coated, 56 tablets | | 1 | 5 | $56.44 | **Coralan**  Servier Laboratories (Aust.) Pty Ltd |  |
|  | | | | | | |
| **Category /**  **Program** | General Schedule | | | | | |
| **Prescriber type:** | Dental Medical Practitioners Nurse practitioners Optometrists  Midwives | | | | | |
| **Episodicity:** | Chronic | | | | | |
| **Severity:** | N/A | | | | | |
| **Condition:** | heart failure | | | | | |
| **PBS Indication:** | Chronic heart failure | | | | | |
| **Treatment phase:** | N/A | | | | | |
| **Restriction Level / Method:** | Restricted benefit  Authority Required - In Writing  Authority Required - Telephone  Authority Required – Emergency  Authority Required - Electronic  Streamlined | | | | | |
| **Treatment criteria:** | N/A | | | | | |
| **Clinical criteria:** | * Patient must be symptomatic with NYHA classes II or III,   **AND**   * Patient must be in sinus rhythm,   **AND**   * Patient must have a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%,   **AND**   * Patient must have a resting heart rate at or above 77 bpm at the time ivabradine treatment is initiated,   **AND**   * Patient must receive concomitant optimal standard chronic heart failure treatment, which must include the maximum tolerated dose of a beta-blocker, unless contraindicated or not tolerated | | | | | |
| **Population criteria:** | N/A | | | | | |
| **Foreword** | N/A | | | | | |
| **Definitions** | N/A | | | | | |
| **Prescriber Instructions** | Resting heart rate should be measured by ECG after 5 minutes rest  The ECG result must be documented in the patient's medical records when treatment is initiated. | | | | | |
| **Administrative Advice** | **Continuing Therapy Only:**  For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners. | | | | | |
| **Cautions** | N/A | | | | | |